Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linezolid + teicoplanin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
A combination of two antibacterial agents used against Gram-positive infections, particularly in critically ill patients. Linezolid is an oxazolidinone that inhibits bacterial protein synthesis by preventing the formation of the initiation complex, binding to the 23S portion of the 50S ribosomal subunit. Teicoplanin is a glycopeptide antibiotic that inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death.
02
Targets
Beyond the preview
Go deeper on linezolid + teicoplanin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linezolid + teicoplanin.